leisure time -WSS

leisure time

author：hotspot 2025-09-27 12:56:16 - browse：33

Primary care exam 01 — ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Why CTE doesn’t keep Americans from enjoying the Super Bowl

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

6 surprising facts about sugar

Biotech investment managers search for lucrative opportunities

Steward Health Care expansion into Malta flopped

knowledge

leisure time

hotspot

Heart attack and stroke risk calculators need revising

Medical devices makers are asking for forgiveness, not permission

Moonlake's readout produced a cash windfall. Risks remain

Testing GLP

Supreme Court strikes down use of affirmative action

Pfizer, Moderna say biotech, pharma drug development is a sprint

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD: Venture capital, Gilead, and more M&A

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Yancopoulos of Regeneron works to expand Dupixent success

entertainment

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Readout Newsletter: Illumina, CRISPR, Regeneron

AstraZeneca stays mum on Medicare drug pricing negotiations

CRISPR technology availability, affordability needs to be expanded

CRISPR technology availability, affordability needs to be expanded

leisure time

focus

knowledge

hotspot